Deutsche Bank Ag\ Esperion Therapeutics, Inc. Transaction History

Deutsche Bank Ag\

$248 Billion
Q4 2024

A detailed history of Deutsche Bank Ag\ transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Deutsche Bank Ag\ holds 166,220 shares of ESPR stock, worth $302,520. This represents 0.0% of its overall portfolio holdings.

Number of Shares

166,220

Previous 1,560,072 89.35%

Holding current value

$302,520

Previous $2.57 Million 85.82%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$1.61 - $3.83 $2.24 Million - $5.34 Million	-1,393,852 Reduced 89.35%	166,220 $365,000
Q3 2024 Nov 13, 2024	BUY	$1.61 - $2.73 $44,997 - $76,300	27,949 Added 1.82%	1,560,072 $2.57 Million
Q2 2024 Aug 14, 2024	BUY	$1.84 - $3.24 $2.82 Million - $4.96 Million	1,532,123 New	1,532,123 $3.4 Million
Q1 2023 May 15, 2023	BUY	$1.46 - $7.3 $22,875 - $114,376	15,668 Added 47.85%	48,413 $76,000
Q4 2022 Feb 13, 2023	BUY	$5.09 - $8.5 $19,988 - $33,379	3,927 Added 13.63%	32,745 $204,000
Q3 2022 Nov 14, 2022	SELL	$5.45 - $8.13 $22,955 - $34,243	-4,212 Reduced 12.75%	28,818 $193,000
Q2 2022 Aug 11, 2022	BUY	$4.77 - $6.67 $12,425 - $17,375	2,605 Added 8.56%	33,030 $210,000
Q1 2022 May 13, 2022	BUY	$3.34 - $5.56 $44,368 - $73,859	13,284 Added 77.5%	30,425 $142,000
Q4 2021 Feb 11, 2022	SELL	$4.81 - $11.92 $9,086 - $22,516	-1,889 Reduced 9.93%	17,141 $86,000
Q3 2021 Nov 04, 2021	SELL	$11.34 - $21.37 $11,169 - $21,049	-985 Reduced 4.92%	19,030 $229,000
Q2 2021 Aug 11, 2021	SELL	$19.4 - $28.71 $16,955 - $25,092	-874 Reduced 4.18%	20,015 $424,000
Q1 2021 May 13, 2021	SELL	$25.12 - $36.89 $39,890 - $58,581	-1,588 Reduced 7.06%	20,889 $585,000
Q4 2020 Feb 16, 2021	BUY	$24.2 - $35.76 $154,444 - $228,220	6,382 Added 39.65%	22,477 $584,000
Q3 2020 Nov 12, 2020	BUY	$31.18 - $52.71 $71,059 - $120,126	2,279 Added 16.5%	16,095 $598,000
Q2 2020 Aug 13, 2020	SELL	$30.04 - $51.31 $4.96 Million - $8.47 Million	-165,119 Reduced 92.28%	13,816 $708,000
Q1 2020 May 14, 2020	SELL	$27.44 - $73.84 $481,325 - $1.3 Million	-17,541 Reduced 8.93%	178,935 $5.64 Million
Q4 2019 Feb 14, 2020	SELL	$35.4 - $59.82 $1.05 Million - $1.78 Million	-29,732 Reduced 13.14%	196,476 $11.7 Million
Q3 2019 Nov 14, 2019	SELL	$34.47 - $47.53 $5.12 Million - $7.05 Million	-148,416 Reduced 39.62%	226,208 $8.29 Million
Q2 2019 Aug 14, 2019	BUY	$40.1 - $52.33 $8.05 Million - $10.5 Million	200,729 Added 115.43%	374,624 $17.4 Million
Q1 2019 May 15, 2019	BUY	$40.11 - $53.57 $6.5 Million - $8.67 Million	161,930 Added 1353.36%	173,895 $6.98 Million
Q4 2018 Feb 14, 2019	SELL	$36.99 - $59.11 $4.79 Million - $7.65 Million	-129,405 Reduced 91.54%	11,965 $550,000
Q3 2018 Dec 21, 2021	BUY	$40.74 - $51.41 $3.89 Million - $4.91 Million	95,451 Added 207.87%	141,370 $6.27 Million
Q3 2018 Nov 14, 2018	SELL	$40.74 - $51.41 $3.19 Million - $4.03 Million	-78,389 Reduced 63.06%	45,919 $2.04 Million
Q2 2018 Apr 21, 2020	BUY	$36.2 - $76.4 $665,175 - $1.4 Million	18,375 Added 17.35%	124,308 $4.87 Million
Q2 2018 Aug 14, 2018	SELL	$36.2 - $76.4 $2.12 Million - $4.47 Million	-58,507 Reduced 35.58%	105,933 $4.15 Million
Q1 2018 Oct 18, 2019	BUY	$65.94 - $80.76 $4.24 Million - $5.19 Million	64,303 Added 64.22%	164,440 $11.9 Million
Q1 2018 May 15, 2018	SELL	$65.94 - $80.76 $4.99 Million - $6.11 Million	-75,650 Reduced 43.04%	100,137 $7.24 Million
Q4 2017 Feb 14, 2018	BUY	$43.47 - $67.43 $2.51 Million - $3.9 Million	57,800 Added 48.99%	175,787 $11.6 Million
Q3 2017 Nov 14, 2017	BUY	$43.8 - $52.77 $5.17 Million - $6.23 Million	117,987	117,987 $5.91 Million

Others Institutions Holding ESPR

# of Institutions

215

Shares Held

129M

Call Options Held

1.78M

Put Options Held

1.27M

View Full List

About Esperion Therapeutics, Inc.

Ticker ESPR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,551,600
Market Cap $121M
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...

More about ESPR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.

Account